Electroacupuncture for nerve pain after breast cancer chemotherapy

Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer

This study is testing if electroacupuncture can help breast cancer patients with nerve pain caused by chemotherapy feel better.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 162 (estimated)
• Ages: 18 Years to 75 Years
• Sex: Female
• Sponsor: Affiliated Hospital of Qinghai University (other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Xining, Qinghai)
• Trial ID: NCT06772935 on ClinicalTrials.gov

What this trial studies

This study investigates the effects of electroacupuncture on peripheral neuropathy caused by taxane chemotherapy in breast cancer patients. It aims to assess the therapeutic benefits of electroacupuncture while also screening for genetic factors related to chemotherapy-induced peripheral neuropathy. Eligible participants will be evaluated using specific quality of life and neurotoxicity scales, and the study may involve multiple groups based on initial findings. The goal is to establish a prognostic model for better management of this condition.

Who should consider this trial

Good fit: Ideal candidates are breast cancer patients aged 18 to 75 who have experienced peripheral neuropathy for at least two weeks after taxane chemotherapy.

Not a fit: Patients with non-breast cancers or those who have received electroacupuncture treatment within the last six months may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for breast cancer patients suffering from chemotherapy-induced nerve pain.

How similar studies have performed: Previous studies have indicated that electroacupuncture may have therapeutic effects on peripheral neuropathy, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria:

* Breast cancer patients diagnosed by pathology;

  * EOOG score is 0 or 1;

    * The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);

      ⑤ Previously received taxane chemotherapy for more than 6 months;

      ⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;

      ⑦ Voluntarily participate in this clinical trial and sign the informed consent form;
      * Accept regular follow-up visits; ⑨ There is complete pathological data available.

Exclusion Criteria:

* Non breast cancer patients;

  * Received electroacupuncture treatment within 6 months prior to the start of the study;

    * Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;

      * Prior to enrollment, there was a history of peripheral neuropathy;

        * Unstable heart disease or myocardial infarction within the first 6 months of the study;

          ⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;

          ⑦ Uncontrolled epilepsy patients with uncontrolled seizures;

          ⑧ Merge with other malignant tumor patients;

          ⑨ Pregnancy and lactation period;

          ⑩ Refusal to join clinical trial patients

Where this trial is running

Xining, Qinghai

• Qinghai University Affiliated Hospital — Xining, Qinghai, China (RECRUITING)

Study contacts

• Study coordinator: Guoshuang Shen G Administrative Director of Breast Center, Affiliated Hospital

Conditions: Breast Cancer, breast cancer, electroacupuncture, taxanes, SNPs, chemotherapy